Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer

ABSTRACT: RATIONALE: Inserting the interleukin-12 gene into a person’s cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases secondary to colorectal cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms,Metastatic Cancer

PROVIDER: 2010050 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Project description:RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person’s white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.

| 2002634 | ecrin-mdr-crc

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Project description:Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person’s white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

| 2003507 | ecrin-mdr-crc

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

Project description:Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons’s white blood cells to kill cancer cells.

| 2002968 | ecrin-mdr-crc

Gene Therapy in Treating Patients With Cancer

Project description:RATIONALE: Inserting a gene that has been created in the laboratory into a person’s white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have cancer that has not responded to previous therapy.

| 2003594 | ecrin-mdr-crc

Characterization of resistance to tumor-localized interleukin-2 and interleukin-12 therapy in pet dogs with advanced malignant melanoma

Project description:Pet dogs with oral melanoma were treated in a dose-escalation trial with collagen-anchored interleukin-2 and interleukin-12 following a single 9Gy dose of radiation therapy. Dogs that progressed during, or after, treatment and were ultimately euthanized had tissue collected from primary and metastatic tumors to analyze gene expression and assess mechanisms of resistance to this therapy.

2024-01-29 | GSE253243 | GEO

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

Project description:RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person’s white blood cells to kill cancer cells. Combining chemotherapy and interleukin-2 may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-2 when given together with bryostatin 1 in treating patients with refractory solid tumors or lymphoma.

| 2003440 | ecrin-mdr-crc

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Project description:RATIONALE: Vaccines made from a person’s white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person’s white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for advanced cancer. PURPOSE: Phase II trial to study the effectiveness of a vaccine made with the patients’ white blood cells mixed with tumor proteins in treating patients who have advanced cancer.

| 2006375 | ecrin-mdr-crc

RNA Sequencing of Intratumoral Immune Populations in Pancreatic Ductal Adenocarcinoma Following Radiotherapy and Interleukin 12 Treatment

Project description:We report differential gene expression in inflammatory monocyte (IM), tumor-associated macrophage (TAM), and CD8 T cell populations following stereotactic body radiation (SBRT), intratumoral interleukin 12 microsphere (IL-12 MS) delivery, and SBRT/IL-12 MS combination. Immune cell populations were sorted from orthotopic murine pancreatic ductal adenocarcinoma (PDA) tumors prior to RNA sequencing.

2020-04-14 | GSE136368 | GEO

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Project description:RATIONALE: Vaccines may make the body build an immune response that will kill cancer cells. Combining vaccine therapy with interleukin-2 may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have locally advanced or metastatic colorectal cancer.

| 2006405 | ecrin-mdr-crc